Ozanimod (RPC-1063)是一种选择性鞘氨醇1-磷酸（S1P）受体调节剂,对S1P1和S1P5受体亚型具有高亲和力,其作用于hS1P1和hS1P5受体的EC50值分别为1.03 nM和8.6 nM。该药物可用于复发性多发性硬化（MS）的相关研究。
|
英文别名 (English Synonym) |
Ozanimod (RPC1063) |
|
中文名称 (Chinese Name) |
奥扎莫德 |
|
靶点 (Target) |
S1P receptor |
|
通路 (Pathway) |
GPCR/G protein |
|
CAS号 (CAS NO.) |
1306760-87-1 |
|
分子式 (Formula) |
C23H24N4O3 |
|
分子量 (Molecular Weight) |
404.46 |
|
纯度 (Purity) |
≥98% |
|
溶解性 (Solubility) |
溶于DMSO |
-25~-15℃保存，有效期3年
[1] Selkirk JV, Dines KC, Yan YG, Ching N, Dalvie D, Biswas S, Bortolato A, Schkeryantz JM, Lopez C, Ruiz I, Hargreaves R. Deconstructing the Pharmacological Contribution of Sphingosine-1 Phosphate Receptors to Mouse Models of Multiple Sclerosis Using the Species Selectivity of Ozanimod, a Dual Modulator of Human Sphingosine 1-Phosphate Receptor Subtypes 1 and 5. J Pharmacol Exp Ther. 2021 Dec,379(3):386-399. doi: 10.1124/jpet.121.000741. Epub 2021 Sep 17. PMID: 34535564.
